Opinion|Videos|October 4, 2024
Urgency to Treat in Lupus Nephritis: Goals of Therapy and Early Diagnosis Strategies
Panelists discuss the goals of therapy for lupus nephritis (LN), emphasizing the urgency of treatment to prevent renal flares and the consequences of untreated LN, as well as strategies for increasing early diagnosis and screening in patients with systemic lupus erythematosus.
Advertisement
Episodes in this series
- What are the goals of therapy for patients with lupus nephritis (LN)? What does urgency to treat mean in LN?
- What are the consequences of untreated LN or renal flares?
Objective: Examine strategies for early diagnosis/screening, updated treatment guidelines, and treatment and payer considerations to optimize lupus nephritis management and address patient access challenges.
- What strategies have you found effective in increasing the screening and early diagnosis of LN in patients with either diagnosed or suspected systemic lupus erythematosus (SLE)?
- Who are these patients who should be screened for LN?
How can payers support screening for LN in patients with SLE?
Advertisement
Related to this article
AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.
A new tool puts this year's measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.
Earlier Alzheimer disease detection is outpacing specialist capacity and may widen gaps for underserved patients, Cleveland experts say.
Young adults with cancer symptoms often fall outside screening guidelines, face costly imaging, and go undiagnosed longer, oncologists say.
Eosinophil thresholds and documentation rules shape COPD biologic access. At ERS 2026, experts discussed biomarkers, delays, and multidisciplinary care.
Oncology leaders discuss where AI delivers value, who bears liability, data readiness, and why humans must stay in the loop for clinical decisions.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
IVF Beats IUI for Early Live Births in Unexplained Infertility
4
Phase 3 Data Back ALP Normalization as Treatment Goal in PBC
5